Latest studies
- Active not recruitingPHASE3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
This study is looking at a new medicine called Olezarsen for people with very high triglyceride levels. It's an ongoing study for those who have already started the treatment in previous trials, checking its long-term safety and how well it's tolerated.
Severe HypertriglyceridemiaCanada - Active not recruitingPHASE3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This study is looking into a new medication called lanifibranor for adults with a liver condition called NASH (Nonalcoholic Steatohepatitis) and significant liver scarring (fibrosis F2 or F3). Researchers want to see if it's safe and helps improve the liver condition.
NASH - Nonalcoholic SteatohepatitisCanada - RecruitingPHASE1, PHASE2
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
This study is testing a new treatment, EP-104GI, for adults with eosinophilic esophagitis (EoE). It aims to see if it's safe, how well it works, and how the body handles it. Participants will either receive the treatment or a dummy version.
Eosinophilic EsophagitisCanada - Active not recruitingPHASE3
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study is looking at how a medication called Tirzepatide might help people living with obesity. Researchers want to see if it can reduce serious health problems and improve overall health in adults.
ObesityOverweightCanada - Enrolling by invitationPHASE3
Long-term Extension of GTX-102 in Angelman Syndrome
This study is looking into the long-term safety and effects of a treatment called GTX-102 for people with Angelman Syndrome. It's for those who have already been in an earlier study with this treatment.
Angelman SyndromeCanada - RecruitingPHASE4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
This study looks at the best time to treat a rare twin pregnancy problem called TRAP sequence. We're comparing treating it early (12-14 weeks) versus later (16-19 weeks) to see which approach works better for the healthy twin. It's a randomised trial, meaning timing is decided by chance.
Twin Reversal Arterial Perfusion SyndromeCanada - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerCanada - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinCanada - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
Breast NeoplasmsCanada - Active not recruitingPHASE3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
This study is looking at two different strengths (50mg and 100mg) of a medicine called ritlecitinib for people aged 12 and over with alopecia areata. It aims to understand how safe and effective the 100mg dose is for hair regrowth.
Alopecia AreataCanada - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
Hot FlashesCanada - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVCanada - RecruitingPHASE1, PHASE2
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
This study is looking for new ways to treat specific childhood cancers that have come back or not responded to previous treatments. It investigates a new medicine called HER3-DXd (also known as patritumab deruxtecan) for safety and effectiveness in children aged 1 month to 17 years with hepatoblastoma or rhabdomyosarcoma.
Malignant NeoplasmCanada - Enrolling by invitationPHASE3
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study looks at the long-term safety of a medicine called eplontersen for adults with a heart condition called ATTR-CM. It's for people who have already taken part in a related study to see how the treatment works over a longer time.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)Canada - RecruitingPHASE3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This study looks at a new gene therapy, Surabgene Lomparvovec, for 'wet' age-related macular degeneration (nAMD). It aims to see if it's safe and effective in reducing the need for frequent eye injections and protecting vision in adults.
Neovascular Age-related Macular DegenerationCanada - Active not recruitingPHASE3
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
This study is testing a new vaccine (mRNA-1345) to protect against Respiratory Syncytial Virus (RSV) in adults at higher risk. It aims to see how safe the vaccine is and how well the body's immune system responds to it. The study involves two groups: high-risk adults and organ transplant recipients.
Respiratory Syncytial VirusCanada - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung CancerHER2 MutationCanada - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
LymphomaCanada - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsCanada - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
This study is testing a new medicine, CAEL-101, for people with a serious heart condition called AL amyloidosis. Researchers want to see if it helps people live longer, reduces hospital stays, and is safe when added to standard treatment.
AL AmyloidosisCanada - Active not recruitingPHASE3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.
Small Cell Lung CancerCanada - Active not recruitingPHASE2
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
This study is testing a new combination of treatments, Intismeran autogene and Pembrolizumab, for kidney cancer. We want to see if this combination, given after surgery, can help stop the cancer from coming back for longer compared to Pembrolizumab alone.
Renal Cell CarcinomaCanada - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaCanada - RecruitingPHASE1
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new medicine called etentamig (ABBV-383) for multiple myeloma that has come back or isn't responding to other treatments. It aims to find out about any side effects and how it affects the disease in adults.
Multiple MyelomaCanada - Enrolling by invitationPHASE2, PHASE3
An Interventional Study of Infigratinib in Children With Hypochondroplasia
This study is looking at a new medicine called infigratinib for children with hypochondroplasia (a type of short stature). It's checking if the medicine is safe and helps children grow better. Children aged 3 to 18 might be able to take part.
HypochondroplasiaCanada - Active not recruiting
Gyrate Atrophy Ocular and Systemic Study
This study looks at how a rare eye condition called Gyrate Atrophy changes over four years. It aims to understand how gene problems affect chemical levels in the body and vision, especially for people using special diets. This information could help develop new treatments.
Gyrate AtrophyGyrata of Choroid and Retina; AtrophyOrnithine-δ-aminotransferaseOATCanada - Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The MOMENTUM Study is tracking how a new type of advanced radiotherapy, called MR-Linac, works for people with different cancers. It aims to see if this treatment improves survival, controls cancer better, and enhances quality of life by using highly precise radiation guidance.
OncologyBreast CancerProstate CancerGynecologic CancerCanada - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
Epithelial Ovarian CancerCanada - RecruitingPHASE2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
This study is for children and adults with a type of high-risk neuroblastoma that hasn't fully responded to previous treatments. It investigates a new approach using two medicines, Naxitamab and GM-CSF, to see if they can help manage the condition.
NeuroblastomaCanada - RecruitingNA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
This study looks at a new way to fix shoulder tendons that are partly torn. It compares a special implant called REGENETEN™ to a standard repair, to see if the implant helps people get back to daily activities faster.
Rotator Cuff InjuriesCanada - Active not recruitingPHASE1, PHASE2
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
This study is testing a new medicine called brenetafusp for people with certain advanced solid cancers that haven't responded to other treatments. It checks how safe and effective brenetafusp is, both alone and with other common cancer drugs.
Select Advanced Solid TumorsCanada - Active not recruitingPHASE2
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This study is looking into a new medication called VHB937 for people with early-stage ALS. We want to see if it's safe and helps improve daily activities and breathing, compared to a dummy drug (placebo).
Amyotrophic Lateral Sclerosis (ALS)Canada - RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaCanada - Active not recruitingPHASE3
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
This study is testing a new medicine, crinecerfont, for adults with a condition called Congenital Adrenal Hyperplasia (CAH). It will compare crinecerfont to a dummy medicine to see if it's safe and helps manage CAH over about 20 months.
Congenital Adrenal HyperplasiaCanada - Active not recruitingPHASE2
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
This study is testing a new treatment, AB-1002, for a type of heart failure called non-ischemic heart failure. It aims to see if it's safe and helps improve symptoms in people whose heart failure is classed as NYHA Class III. Patients will be randomly assigned to receive the treatment or a placebo.
Congestive Heart FailureCanada - Active not recruitingPHASE3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.
Rheumatoid ArthritisCanada - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
Various Advanced CancerCanada - Active not recruitingPHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
This study looks at a new drug, evorpacept, combined with an existing one, pembrolizumab, for advanced head and neck cancer. It aims to see if this combination works better than pembrolizumab alone for patients who haven't had treatment for advanced stages of their cancer. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
Head and Neck CancerHead and Neck Squamous Cell CarcinomaCanada - Active not recruitingPHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.
Breast CancerCanada - RecruitingPHASE2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
This study explores a new treatment for aggressive bladder cancer that hasn't spread to the muscle. Researchers are testing if adding a new drug, intismeran autogene, to standard treatment (BCG) helps patients live longer without their cancer growing or returning. It's for adults with high-risk non-muscle invasive bladder cancer.
Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in SituCanada - RecruitingPHASE2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This study looks at a new treatment called LN-145 for advanced lung cancer (non-small cell type) that has spread. It involves using your own immune cells to fight the cancer. Researchers want to see how safe and effective this treatment is.
Metastatic Non Small Cell Lung CancerCanada - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
ER-Positive HER2-Negative Breast CancerCanada - RecruitingPHASE3
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
This study looks at a new medicine called benralizumab for children aged 6 to 18 with severe asthma. It wants to see if the medicine can stop asthma attacks and if it's safe. Half the children get the medicine, and half get a dummy medicine.
AsthmaCanada - Active not recruitingPHASE4
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
This study is looking at a new treatment called guselkumab for people with psoriatic arthritis that affects the spine and pelvis. It aims to see how well it reduces pain and inflammation in these areas. Participants will receive either the study drug or a dummy treatment.
Arthritis, PsoriaticCanada - Active not recruitingPHASE1, PHASE2
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
This study is looking into an experimental vaccine for Cytomegalovirus (CMV), a common virus. It aims to check its safety and how well it helps the body fight off the virus in healthy young people aged 9 to 25.
CytomegalovirusCanada - RecruitingPHASE2
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
This study is looking at a new treatment called Ultevursen for a type of eye problem called Retinitis Pigmentosa (RP) caused by specific gene changes. It's in the second stage of testing, focusing on how safe and well people tolerate the treatment when it's given as an injection into the eye.
Retinitis Pigmentosa (RP)Usher Syndrome Type 2Deaf BlindRetinal DiseaseCanada - Recruiting
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
This study looks at how QUVIVIQ, a medicine for insomnia, might affect pregnant women and their babies. We want to compare women who took QUVIVIQ during pregnancy with those who took other insomnia medicines or no medicine at all, to understand the outcomes for mothers and their newborns.
InsomniaCanada - Active not recruitingPHASE2
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This study is testing a new medicine, bezuclastinib, for people with certain types of mastocytosis (a rare blood disorder). It compares bezuclastinib with a dummy pill (placebo) to see if it safely helps reduce symptoms that aren't well controlled by current treatments.
SSMMastocytosis, IndolentMastocytosis, SystemicMastocytosisCanada - Not yet recruitingPHASE3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.
Extrapulmonary Neuroendocrine CancerCanada - RecruitingPHASE3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
This study is testing a new medicine, enlicitide, for high cholesterol. Researchers want to see if combining enlicitide with a common cholesterol medicine, rosuvastatin, works better at lowering 'bad' cholesterol than rosuvastatin alone. It's for adults aged 18-64.
HyperlipidemiaCanada